Active	Status	Sponsor type	Region	Phase	Filter
15 Active 0 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wayne, Jeffrey
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	Active, not recruiting	4	780	Europe, Canada, US, RoW	Tirzepatide, LY3298176, Antihyperglycemic medication	Eli Lilly and Company	Type 2 Diabetes	10/25	11/27
REGAiN-1B, NCT04873232: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy	Completed	3	106	US	Engensis, Placebo	Helixmith Co., Ltd.	Diabetic Peripheral Neuropathy	09/23	07/24
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension	Active, not recruiting	3	1083	Europe, Canada, US, RoW	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	12/24	02/25
NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)	Completed	3	1570	Europe, Canada, US, RoW	Estetrol, Placebo, Progesterone	Estetra, ICON Clinical Research	Vasomotor Symptoms, Menopausal Symptoms	02/24	02/24
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia	Recruiting	3	300	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Active, not recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Active, not recruiting	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	02/25
Sussman, Jeffrey
No trials found